NG
VRTX icon

NatWest Group’s Vertex Pharmaceuticals VRTX Stock Holding History

NatWest Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,691
Closed -$2.8M – 39
2024
Q1 		$2.8M Sell
6,691
-203
-3% -$85.8K 1.08% 28
2023
Q4 		$2.81M Buy
6,894
+1,068
+18% +$395K 1.17% 27
2023
Q3 		$2.03M Buy
5,826
+127
+2% +$44.4K 1.06% 28
2023
Q2 		$2.01M Buy
5,699
+14
+0.2% +$4.72K 1.04% 28
2023
Q1 		$1.79M Sell
5,685
-13,639
-71% -$4.09M 0.97% 30
2022
Q4 		$5.58M Buy
19,324
+406
+2% +$124K 3.17% 10
2022
Q3 		$5.48M Buy
+18,918
New +$5.44M 3.18% 9
2015
Q4 		– Sell
-7,054
Closed -$735K – 337
2015
Q3 		$735K Buy
+7,054
New +$906K 0.02% 223
2015
Q2 		– Sell
-7,664
Closed -$904K – 430
2015
Q1 		$904K Buy
7,664
+4,961
+184% +$594K 0.01% 231
2014
Q4 		$321 Buy
+2,703
New +$304K ﹤0.01% 369
2014
Q2 		– Sell
-15,145
Closed -$1.07M – 601
2014
Q1 		$1.07M Sell
15,145
-18,518
-55% -$1.47M 0.05% 237
2013
Q4 		$2.5M Buy
33,663
+5,629
+20% +$392K 0.06% 246
2013
Q3 		$2.13M Buy
28,034
+158
+0.6% +$12.6K 0.06% 252
2013
Q2 		$2.23M Buy
+27,876
New +$2.05M 0.03% 298

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

NatWest Group's VRTX Position: Q2 2024 in Review

NatWest Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 6,691 shares — an estimated $2.8M sold.

NatWest Group first reported a position in VRTX in Q2 2013 and held it in 14 quarters. The position peaked at $5.58M in Q4 2022. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • NatWest Group reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • NatWest Group sold 6,691 Vertex Pharmaceuticals shares in Q2 2024, an estimated $2.8M.
  • NatWest Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • NatWest Group's Vertex Pharmaceuticals position peaked at $5.58M in Q4 2022.
  • 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on NatWest Group's 13F filing for Q2 2024, filed 19 Jul 2024.